KBC Group’s Syndax Pharmaceuticals SNDX Stock Holding History

KBC Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$72K	Sell	3,062 -2,118	-41%	-$46K	﹤0.01%	1498
2025 Q4	$109K	Hold	5,180	–	–	﹤0.01%	1220
2025 Q3	$80K	Hold	5,180	–	–	﹤0.01%	1401
2025 Q2	$49K	Hold	5,180	–	–	﹤0.01%	1617
2025 Q1	$64K	Sell	5,180 -1,774	-26%	-$25K	﹤0.01%	1716
2024 Q4	$92K	Buy	6,954 +3,559	+105%	+$60.9K	﹤0.01%	1617
2024 Q3	$65K	Hold	3,395	–	–	﹤0.01%	1577
2024 Q2	$70K	Buy	+3,395	New	+$71K	﹤0.01%	1420

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

KBC Group's SNDX Position: Q1 2026 in Review

KBC Group reduced its Syndax Pharmaceuticals (SNDX) stake by 41% in Q1 2026, selling an estimated $46K and leaving 3,062 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

KBC Group first reported a position in SNDX in Q2 2024 and has held it in 8 quarters since. The position peaked at $109K in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

KBC Group held 3,062 shares of Syndax Pharmaceuticals worth $72K as of Q1 2026.
KBC Group sold 2,118 Syndax Pharmaceuticals shares in Q1 2026, an estimated $46K.
Syndax Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1498 holding.
KBC Group first reported a position in Syndax Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
KBC Group's Syndax Pharmaceuticals position peaked at $109K in Q4 2025.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.